Pfizer Inc. (ETR: PFE)
Germany
· Delayed Price · Currency is EUR | Market Cap | 144.66B |
| Revenue (ttm) | 53.18B |
| Net Income (ttm) | 3.81B |
| Shares Out | n/a |
| EPS (ttm) | 0.67 |
| PE Ratio | 37.98 |
| Forward PE | n/a |
| Dividend | 1.55 (6.13%) |
| Ex-Dividend Date | Jan 24, 2025 |
| Volume | 24,054 |
| Open | 25.51 |
| Previous Close | 25.62 |
| Day's Range | 25.37 - 25.60 |
| 52-Week Range | 23.25 - 29.50 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 4, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]
Financial Performance
In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.
Financial numbers in USD Financial StatementsNews
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr.
This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, and Merck. Read more here.
Dividend Harvesting Portfolio Week 199: $19,900 Allocated, $1,908.79 In Projected Dividends
Despite recent declines, the Dividend Harvesting Portfolio remains profitable, generating $1,908.79 in forward dividend income with a 23.38% return on invested capital. I believe the Fed's rate cuts a...
Pfizer: Why I'm Staying On The Sidelines
Pfizer trades at a 21.7% discount to peers on a 1-yr forward P/E basis, which is a point for the bullish arguments. Find out why I am neutral on PFE stock.
Javed Mirza's Top Picks: Tamarack Valley Energy, Peyto Exploration & Development and Pfizer
Raymond James technical strategist Javed Mirza shares his top picks; Tamarack Valley Energy, Peyto Exploration & Development and Pfizer.
Enanta Pharmaceuticals (ENTA) Appeals Court Ruling in Patent Dispute with Pfizer (PFE)
Enanta Pharmaceuticals (ENTA) Appeals Court Ruling in Patent Dispute with Pfizer (PFE)
Pfizer: Time And Patience Ran Out (Rating Downgrade)
Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained turnaround is close for PFE stock.
If You Could Only Buy One: 5 Top Dividend Stocks For The Next 10 Years
I'm not a fan of New Year's Eve or market predictions. To shift the focus, I asked followers to select a single stock for a 10-year investment horizon. The responses were intriguing, ranging from a de...
Enanta to appeal as Pfizer wins Paxlovid patent ruling
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United ...
Luigi Mangione's judge Katharine Parker married to former healthcare executive: Reports
Judge Katharine H Parker, handling Luigi Mangione's pre-trial hearings, is married to a former Pfizer executive and holds Pfizer stock. Mangione is accused of killing UnitedHealthcare CEO Brian Thomps...
This Is What Whales Are Betting On Pfizer
High-rolling investors have positioned themselves bullish on Pfizer (NYSE: PFE), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's trac...
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2. Goldman...
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. diff) vaccine effort in Phase 2.
Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked
Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.
Pfizer Just Reassured Investors, but Is the Stock a Buy?
‘Heartless’ multinationals exploiting pensions loophole for UK workers
Hewlett Packard, American Express and Pfizer among firms to have frozen increases in payouts despite inflation Some of the world’s richest companies are accused of exploiting a loophole in pension law...
Market Today: Qualcomm's Legal Victory and Pfizer's FDA Approval Highlight Key Developments
Market Today: Qualcomm's Legal Victory and Pfizer's FDA Approval Highlight Key Developments
Pfizer gets FDA accelerated approval for Braftovi
Pfizer Inc (PFE) Gains FDA Approval for New Colorectal Cancer Treatment
Pfizer Inc (PFE) Gains FDA Approval for New Colorectal Cancer Treatment
U.S. FDA Approves Pfizer’s BRAFTOVI Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluoroura...
U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBI...
Pfizer Inc (PFE) Announces Upcoming Webcast for Fourth Quarter and Full Year 2024 Performance Report
Pfizer Inc (PFE) Announces Upcoming Webcast for Fourth Quarter and Full Year 2024 Performance Report
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The purpo...
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, ...